Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
1998-09-22
Achutamurthy, Ponnathapura
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
424135, 4241471, 4243913, 4351723, 536 2353, C07K 1600, A61K 39395, C12N 1500, C07H 2104
Patent
active
058115242
ABSTRACT:
A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein about 2.times.10.sup.-9 to 10.sup.-10 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
REFERENCES:
patent: 4517304 (1985-05-01), Stott et al.
patent: 4659563 (1987-04-01), Dobkin
patent: 4717766 (1988-01-01), Dobkin
patent: 4760026 (1988-07-01), Lennox et al.
patent: 4800078 (1989-01-01), Prince et al.
patent: 4853326 (1989-08-01), Quash et al.
patent: 5071758 (1991-12-01), Stott et al.
patent: 5137804 (1992-08-01), Greene et al.
patent: 5149650 (1992-09-01), Wertz et al.
patent: 5183657 (1993-02-01), Buurman
patent: 5194595 (1993-03-01), Wathen
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5223254 (1993-06-01), Paradiso et al.
patent: 5240694 (1993-08-01), Gwaltney, Jr.
patent: 5271927 (1993-12-01), Parker et al.
patent: 5279935 (1994-01-01), Nycz
patent: 5288630 (1994-02-01), Wathen
patent: 5290540 (1994-03-01), Prince et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5332805 (1994-07-01), Carey et al.
patent: 5340926 (1994-08-01), Lowe et al.
patent: 5354554 (1994-10-01), Rhind
patent: 5391478 (1995-02-01), Greene et al.
patent: 5412077 (1995-05-01), Siber et al.
patent: 5418136 (1995-05-01), Miller et al.
patent: 5422097 (1995-06-01), Gwaltney, Jr.
patent: 5424189 (1995-06-01), Oberst et al.
patent: 5468606 (1995-11-01), Bogart et al.
patent: 5470736 (1995-11-01), Verma et al.
patent: 5484893 (1996-01-01), Parker et al.
patent: 5506209 (1996-04-01), Mukerji et al.
patent: 5518725 (1996-05-01), Daynes et al.
patent: 5530102 (1996-06-01), Gristina et al.
patent: 5534411 (1996-07-01), Weltzin
patent: 5538733 (1996-07-01), Emery et al.
patent: 5538952 (1996-07-01), Mukerji et al.
Paul W,E. 1993 Fundamental Immunology p. 242.
Seaver 1994 Genetic Engineering vol. 14(14) pp. 10 and 21.
Brams Peter
Chamat Soulaima Salim
Heard Cheryl Janne
Newman Roland Anthony
Pan Li-Zhen
Achutamurthy Ponnathapura
Idec Pharmaceuticals Corporation
Park Hankyel T.
LandOfFree
Neutralizing high affinity human monoclonal antibodies specific does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing high affinity human monoclonal antibodies specific , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing high affinity human monoclonal antibodies specific will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1622690